Vector Science & Therapeutics Reports First Quarterly Financials as Public Company; Schedules Investor Q&A
Vector Science & Therapeutics Corp. disclosed its first quarterly financial results as a public entity following its go-public transaction in April 2026. The company anticipates its peptide manufacturing division will commence revenue generation in August 2026.
MEQUON, Wisconsin – Vector Science & Therapeutics Corp. announced on July 24, 2026, the filing of its initial quarterly financial statements and Management's Discussion & Analysis since becoming a public company in April 2026.
The company's peptide manufacturing operations are set to begin generating revenue in August 2026, with production capacity projected to reach approximately 800,000 vials per month by early fall. Furthermore, VectorMist™, a product for perioperative pain management in laparoscopic surgery, is on track for a 510(k) submission to the FDA, with distribution discussions already underway.
Vector Science & Therapeutics will host its inaugural quarterly investor question-and-answer session on Tuesday, July 28, 2026, at 12:00 PM Eastern Time via Microsoft Teams. This session is expected to provide insights into the company's strategic direction and future plans.
The company is focusing on commercializing two primary verticals: cGMP peptide manufacturing and VectorMist™ for laparoscopic pain management. Both are targeted for revenue generation within 2026. Vector Science & Therapeutics aims to capitalize on the growing peptide market and enhance the delivery of therapeutic compounds.